Advanced Glycation End Products Induced Mitochondrial Dysfunction of Chondrocytes through Repression of AMPKα-SIRT1-PGC-1α Pathway
Pharmacology · 2022 · 107 (5-6) · 298-307
DOI: 10.1159/000521720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, online erschienen am 03.03.2022. Verfasst von Qingshan Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Gan Su Province Hospital, Lan Zhou, China. Hauptthemen laut MEDLINE: Osteoarthritis, Sirtuin 1. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Introduction
Our previous studies have demonstrated advanced glycation end products (AGEs) was an important mediator in osteoarthritis (OA) which may induce mitochondrial dysfunction. AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and its downstream target peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) are the critical sensors that regulate mitochondrial biogenesis and have been recognized as therapeutic targets in OA. This study was designed to test whether AGEs caused mitochondrial dysfunction through modulation of AMPKα/SIRT1/PGC-1α.
Methods
We knocked down or overexpressed AMPKα, SIRT1, and PGC-1α by small interfering RNA or plasmid DNA transfection, respectively. Mitochondrial membrane potential (△Ψ) was detected by tetraethylbenzimidazolyl carbocyanine iodide (JC-1) fluorescence probe.
Results
The results showed that AGEs impaired △Ψ, intracellular ATP level, and mitochondrial DNA content, linked to decreased AMPKα, SIRT1, and PGC-1α expression in chondrocyte. AMPKα pharmacologic activation or overexpression of AMPKα, SIRT1, and PGC-1α reversed impairments of mitochondrial biogenesis, oxidative stress, and inflammation in AGEs-induced chondrocytes. However, AMPKα activation using AICAR had decreased capacity to increase each of those same effect readouts in AGEs-treated SIRT1-siRNA or PGC-1α-siRNA chondrocyte.
Conclusion
Taken together, AGEs reduced the AMPKα/SIRT1/PGC-1α signaling in chondrocytes, leading to mitochondrial dysfunction as a result of increased oxidative stress, inflammation, and apoptosis. These results indicated that target AMPK may be as a novel therapeutic strategy for AGEs-related OA prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, Gan Su Province Hospital, Lan Zhou, China.
- Gansu University of Chinese Medicine, Lan Zhou, China.
- Department of Pharmacy, Gan Su ProvincTe Hospital, Lan Zhou, China.
Zitieren
APA
Yang, Q., Shi, Y., Jin, T., Duan, B., & Wu, S. (2022). Advanced Glycation End Products Induced Mitochondrial Dysfunction of Chondrocytes through Repression of AMPKα-SIRT1-PGC-1α Pathway. Pharmacology, 107(5-6), 298-307. https://doi.org/10.1159/000521720
Vancouver
Yang Q, Shi Y, Jin T, Duan B, Wu S. Advanced Glycation End Products Induced Mitochondrial Dysfunction of Chondrocytes through Repression of AMPKα-SIRT1-PGC-1α Pathway. Pharmacology. 2022;107(5-6):298-307. doi:10.1159/000521720
BibTeX
@article{Yang2022,
author = {Yang, Qingshan and Shi, Yucong and Jin, Tao and Duan, Bowen and Wu, Shujin},
title = {Advanced Glycation End Products Induced Mitochondrial Dysfunction of Chondrocytes through Repression of AMPKα-SIRT1-PGC-1α Pathway},
journal = {Pharmacology},
year = {2022},
volume = {107},
number = {5-6},
pages = {298--307},
doi = {10.1159/000521720}
}
EUVIMED